Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METLung: Onartuzumab + Erlotinib in MET-positive NSCLC
NCT01456325Phase 3Completed
- Sponsor
- Genentech
- Start
- Jan 2012
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of onartuzumab in non-small cell lung cancer (NSCLC), sponsored by Genentech. Started Jan 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01456325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01456325.